Compare Keysight Technologies Inc (KEYS) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs Philip Morris International Inc. — how do they compare? Keysight Technologies Inc trades at $385.48 (market cap $63.79B), while Philip Morris International Inc. trades at $200.5 (market cap $312.50B). The key difference: Philip Morris International Inc. is far larger — about 4.9× Keysight Technologies Inc's market cap, and Philip Morris International Inc. pays a 3.19% dividend while Keysight Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Keysight Technologies Inc for 56 Days and Philip Morris International Inc. for 85 Days on average.
| KEYS | PM | |
|---|---|---|
Market Cap | $63.79B | $312.50B |
Volume | 1,435,384 | 5,517,172 |
Sector | Technology | Consumer Staples |
52-Week High | $387.90 | $200.50 |
52-Week Low | $159.49 | $144.33 |
Typical Hold Time | 56 Days | 85 Days |
Enterprise Value | $63.93B | $355.62B |
Dividend Yield | — | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keysight Technologies (KEYS) trades at $382.75, up 0.33% with strong technical momentum as it approaches resistance at $385. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $3.07 versus $2.48, supported by 19.14% net margins and 20.59% ROE. Recent news highlights AI infrastructure demand and 6G development opportunities, with orders surging 56% in Q3 2026.
Wall Street maintains strong bullish sentiment with 81% buy ratings and $416.63 consensus target, though elevated P/E of 50.7 presents valuation risk. Growth catalysts include AI data-center expansion and 6G wireless development, while risks involve supply constraints and competitive pressures in the testing equipment market.
Philip Morris International (PM) trades at $192.69, up 1.2% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 EPS beat expectations at $2.20 vs. $2.05, and revenue growth accelerated to $40.65B in 2025. The company's smoke-free products now drive 42% of revenue, with ZYN and IQOS expansions fueling optimism. Cash flow remains robust, with 2026 operating cash flow projected at $14.3B, supporting dividend growth.
Outlook is positive given earnings momentum and smoke-free transition, but high debt ($42.17B long-term) and regulatory risks persist. The consensus price target of $212.17 implies ~10% upside, though valuation multiples are elevated versus peers. Key risks include FX volatility and slower adoption of next-gen products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
